|
|
Lawrence Steinman
J Clin Invest. 2008;
118(11):3557
doi:10.1172/JCI36532
Abstract |
Full text
| PDF
T
he three most prevalent human disorders of the CNS in which immunity and inflammation are likely to have vital roles (excluding infection of the CNS) are fever, multiple sclerosis (MS), and Alzheimer disease (AD). As reviewed here, cytokines are critical in the induction of fever, the pathogenesis of MS, and the pathobiology of AD. Indeed, antibodies targeting cytokines have been used as a therapy for individuals with unusual and persistent febrile reactions not responsive to common antipyretics, while a recombinant cytokine is the most popular treatment for the relapsing-remitting form of MS. Although cytokine-modulating therapies are not currently in clinical use for the treatment of AD, cytokines can ameliorate disease pathology in certain experimental models of AD, suggesting a potential for future therapeutic opportunities.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(27)
| Title and authors |
Publication |
Year |
Immunotherapeutic implication of IL-6 blockade
Toshio Tanaka, Tadamitsu Kishimoto
|
Immunotherapy
|
2012 |
Therapeutic Targeting of the Interleukin-6 Receptor
Toshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
|
Annu. Rev. Pharmacol. Toxicol.
|
2012 |
Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases
Toshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
|
FEBS Letters
|
2011 |
Autoimmune and inflammatory mechanisms of CNS damage
Minesh Kapadia, Boris Sakic
|
Progress in Neurobiology
|
2011 |
CCL2 binding is CCR2 independent in primary adult human astrocytes
A. Fouillet, J. Mawson, O. Suliman, B. Sharrack, I.A. Romero, M.N. Woodroofe
|
Brain Research
|
2011 |
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders
Toshio Tanaka, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata, Atsushi Kumanogoh
|
Drug Dev. Res.
|
2011 |
Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis
Chang Wook Lee, Ji Woong Choi, Jerold Chun
|
Arch. Pharm. Res.
|
2010 |
Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis
Giuseppe Scalabrino, Daniela Galimberti, Elena Mutti, Diego Scalabrini, Daniela Veber, Milena De Riz, Fabrizia Bamonti, Elisabetta Capello, Giovanni Luigi Mancardi, Elio Scarpini
|
Brain Research
|
2010 |
Antidepressant Effects on Insulin Sensitivity and Proinflammatory Cytokines in the Depressed Males
Yi-Chyan Chen, Wei-Win Lin, Yu-Jung Chen, Wei-Chung Mao, Yi-Jen Hung
|
Mediators of Inflammation
|
2010 |
What drives disease in multiple sclerosis: Inflammation or neurodegeneration?
Hans Lassmann
|
Clinical and Experimental Neuroimmunology
|
2010 |
|